Clinical trials for B-cell non-Hodgkin lymphoma
100 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 1NCT07133997Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaCity of Hope Medical Center · PI: Amandeep Salhotra
- RECRUITINGPhase 1NCT07361224Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.Tel-Aviv Sourasky Medical Center · PI: Ron Ram, Prof.
- RECRUITINGPhase 2NCT07523737Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell LymphomaBeijing Tongren Hospital · PI: Liang Wang, M.D.
- RECRUITINGPHASE1, PHASE2NCT07283679Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaM.D. Anderson Cancer Center · PI: Yago Nieto, MD,PHD
- RECRUITINGPHASE1, PHASE2NCT07135466A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell MalignanciesSheba Medical Center · PI: Prof. Elad Jacoby, MD
- ACTIVE NOT RECRUITINGNCT07480837Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin LymphomaCancer Institute and Hospital, Chinese Academy of Medical Sciences · PI: Xinxin Cao, MD
- ACTIVE NOT RECRUITINGPhase 2NCT07480850Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell LymphomaCancer Institute and Hospital, Chinese Academy of Medical Sciences · PI: Cao Xinxin
- RECRUITINGEarly Phase 1NCT07376642A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin LymphomaSuzhou Immunofoco Biotechnology Co., Ltd
- RECRUITINGNCT06994169Glofitamab in Real LifeThe Lymphoma Academic Research Organisation · PI: Guillaume MANSON, MD
- RECRUITINGNCT07233720Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone LymphomaHenan Cancer Hospital · PI: Zhihua Yao, M.D. Ph.D
- RECRUITINGPhase 2NCT07125872Study of Relapsed/ Refractory B-cell Non- Hodgkin LymphomaImmunityBio, Inc.
- RECRUITINGPhase 2NCT06300528Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomasUniversity of Utah · PI: Narendranath Epperla, MD, MS
- RECRUITINGN/ANCT06850285CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory LymphomaShanxi Bethune Hospital · PI: jia wei
- RECRUITINGPhase 2NCT06784726Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-TUniversity of Washington · PI: Mengyang Di, MD, PhD
- RECRUITINGPhase 2NCT06508931Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell NeoplasmsMiltenyi Biomedicine GmbH · PI: Birgit Burkhardt, Prof. Dr.
- RECRUITINGPhase 1NCT07053670A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )Tongji Hospital
- RECRUITINGPhase 1NCT07072169A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)Ruijin Hospital · PI: Wei li Zhao
- RECRUITINGPhase 1NCT07260812KSV01 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin LymphomaTCRx Therapeutics Co.Ltd
- RECRUITINGPhase 1NCT06624085A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaHoffmann-La Roche · PI: Clinical Trials
- RECRUITINGPhase 2NCT06835530A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)Fondazione Italiana Linfomi - ETS · PI: Alessandra Tucci, Dr.ssa
- ACTIVE NOT RECRUITINGPhase 2NCT07094477Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell LymphomaDaihong Liu · PI: Dai-Hong Liu, Dr.
- RECRUITINGPhase 1NCT06822868A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin LymphomaKai Hu
- RECRUITINGPhase 1NCT05990465LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell MalignanciesMedical College of Wisconsin · PI: Nirav Shah, MD
- RECRUITINGPhase 1NCT06820268A Study of XS-04 in Patients with Relapsed or Refractory Hematologic MalignanciesNovaOnco Therapeutics Co., Ltd.
- RECRUITINGPhase 1NCT06734871A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin LymphomaAibin Liang，MD，Ph.D. · PI: Aibin Liang MD,Ph.D.
- RECRUITINGPhase 1NCT06707259Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHLSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPhase 2NCT06484920A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHLRita Assi · PI: Rita Assi, MD
- RECRUITINGPhase 2NCT06589089Autologous Hematopoietic Stem Cell Boost Study After CAR-T TherapyRuijin Hospital
- RECRUITINGPhase 1NCT06392477A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin LymphomaSanofi · PI: Clinical Sciences & Operations
- RECRUITINGNCT06497452A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.The First Affiliated Hospital of Soochow University
- ACTIVE NOT RECRUITINGPhase 1NCT06470438A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's LymphomaJanssen Research & Development, LLC · PI: Janssen Research & Development, LLC Clinical Trial
- RECRUITINGN/ANCT06389305CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell DysfunctionBeijing GoBroad Hospital
- RECRUITINGPHASE1, PHASE2NCT06552559Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin LymphomaSamsung Medical Center · PI: Seok Jin Kim
- RECRUITINGPHASE1, PHASE2NCT06002659CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)Uppsala University · PI: Di Yu, PhD
- RECRUITINGPHASE1, PHASE2NCT06323525TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell LymphomaChinese PLA General Hospital
- RECRUITINGPhase 2NCT06365671CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic FactorsRuijin Hospital
- RECRUITINGPhase 1NCT06251180Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin LymphomaGuangzhou Lupeng Pharmaceutical Company LTD. · PI: Qingqing Cai, Ph D
- ACTIVE NOT RECRUITINGN/ANCT06090162LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin LymphomaSwiss Cancer Institute · PI: Noémie Lang, MD
- RECRUITINGPHASE1, PHASE2NCT06088654Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin LymphomaInnate Pharma
- ACTIVE NOT RECRUITINGPhase 1NCT05737628First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228Byondis B.V. · PI: Norbert Koper
- RECRUITINGPhase 2NCT06381830Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's LymphomaThe First Affiliated Hospital of Soochow University · PI: Deipei Wu, M.D.
- RECRUITINGEarly Phase 1NCT06693973An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's LymphomaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPhase 1NCT06028373A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin LymphomasAntengene Biologics Limited
- RECRUITINGNCT05541341Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte MalignanciesNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPhase 1NCT05784441A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)Janssen Research & Development, LLC · PI: Janssen Research & Development, LLC Clinical Trial
- RECRUITINGPHASE1, PHASE2NCT05702853Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLLMedical University of South Carolina · PI: Brian Hess, PHD
- RECRUITINGPhase 2NCT05852717Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell LymphomaDipenkumar Modi · PI: Dipenkumar Modi, MD
- RECRUITINGPhase 2NCT06176729Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL PatientsYan Zhang, MD · PI: Yan Zhang, MD
- RECRUITINGNCT06357754Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary MalignancyBristol-Myers Squibb · PI: Bristol-Myers Squibb
- RECRUITINGPhase 2NCT05890352Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentSWOG Cancer Research Network · PI: Jennifer E Amengual
- RECRUITINGPhase 1NCT05365659IKS03 in Patients With Advanced B Cell Non-Hodgkin LymphomasIksuda Therapeutics Ltd. · PI: Paul I Nadler, MD
- ACTIVE NOT RECRUITINGNCT05954910A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell LymphomaHoffmann-La Roche · PI: Clinical Trials
- RECRUITINGPhase 1NCT05432635Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin LymphomaCity of Hope Medical Center · PI: Alex Herrera
- RECRUITINGPHASE1, PHASE2NCT05806099A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHLBeijing Mabworks Biotech Co., Ltd.
- RECRUITINGPhase 1NCT05389423Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasNational Cancer Institute (NCI) · PI: Ramya M Ramaswami, M.D.
- RECRUITINGPhase 1NCT05794958Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-CelStanford University · PI: Saurabh Dahiya, MD
- RECRUITINGPhase 1NCT06565689A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012Excyte Biopharma Ltd · PI: Yuankai Shi, MD
- RECRUITINGNCT06625203A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in OncologyOWKIN · PI: Dr. Vassili Soumelis
- RECRUITINGPhase 2NCT05615636A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLM.D. Anderson Cancer Center · PI: Jason Westin, MD, MS, FACP
- ACTIVE NOT RECRUITINGPhase 1NCT05400109Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin LymphomasDavid Wald · PI: Changchun Deng, MD, PhD
- RECRUITINGPhase 1NCT05755087Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell LymphomaLapo Alinari · PI: Lapo Alinari, MD, PhD
- RECRUITINGPHASE1, PHASE2NCT05455697Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell LymphomaUniversity of Washington · PI: Stephen D. Smith
- RECRUITINGPhase 1NCT05272384Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaNational Cancer Institute (NCI) · PI: Catherine S Diefenbach
- RECRUITINGPhase 2NCT05846750Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone LymphomaInstitute of Hematology & Blood Diseases Hospital, China · PI: Shuhua Yi, Dr
- RECRUITINGPhase 2NCT05641428Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCLUniversity Medical Center Groningen · PI: T. (Tom) van Meerten
- ACTIVE NOT RECRUITINGPhase 3NCT07226752A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in ChinaGenmab · PI: Study Official
- ACTIVE NOT RECRUITINGPhase 1NCT05574114A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell LymphomaMemorial Sloan Kettering Cancer Center · PI: Lia Palomba, MD
- ACTIVE NOT RECRUITINGPhase 1NCT05540340A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell TransplantMemorial Sloan Kettering Cancer Center · PI: Parastoo Dahi, MD
- RECRUITINGN/ANCT05618041The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological MalignanciesHebei Senlang Biotechnology Inc., Ltd. · PI: Weiwei w Tian, MD
- RECRUITINGPHASE1, PHASE2NCT05421663A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin LymphomaJanssen Research & Development, LLC · PI: Janssen Research & Development, LLC Clinical Trial
- RECRUITINGPhase 1NCT05472558Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHLSecond Affiliated Hospital, School of Medicine, Zhejiang University · PI: Wenbin Qian
- RECRUITINGPhase 1NCT04970901A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)ADC Therapeutics S.A.
- ACTIVE NOT RECRUITINGPhase 2NCT05335018GPL in Patients with Relapsed/refractory Diffuse Large B Cell LymphomaSeoul National University Hospital · PI: Sung-soo Yoon
- RECRUITINGPhase 2NCT04840602Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaNational Cancer Institute (NCI) · PI: Sikander Ailawadhi
- ACTIVE NOT RECRUITINGPhase 2NCT05020015A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)Takeda · PI: Medical Director
- RECRUITINGPhase 1NCT06725524A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin LymphomaShanghai JMT-Bio Inc. · PI: Weili Zhao
- RECRUITINGPhase 2NCT05436223Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's LymphomaHrain Biotechnology Co., Ltd. · PI: Peng Liu, M.D. & Ph.D.
- RECRUITINGPhase 1NCT04739813Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaNational Cancer Institute (NCI) · PI: Christopher J Melani, M.D.
- RECRUITINGPhase 2NCT06698484To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)National University of Malaysia
- RECRUITINGPhase 1NCT06189391A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)MSD R&D (China) Co., Ltd. · PI: Medical Director
- RECRUITINGPHASE1, PHASE2NCT04544592UCD19 CarT in Treatment of Pediatric B-ALL and B-NHLUniversity of Colorado, Denver · PI: Vanessa Fabrizio, MD, MS
- RECRUITINGPhase 1NCT04594642A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin LymphomaAstraZeneca · PI: David Sermer, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04718883CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell LymphomaShanghai Ming Ju Biotechnology Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04257578Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell LymphomaUniversity of Washington · PI: Ajay Gopal
- ACTIVE NOT RECRUITINGNCT04333524FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic RoleInternational Extranodal Lymphoma Study Group (IELSG) · PI: Stefano Luminari, MD
- ACTIVE NOT RECRUITINGPhase 1NCT05395533A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.Zhejiang Teruisi Pharmaceutical Inc. · PI: Yuankai Shi, MD
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT04442022A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaKaryopharm Therapeutics Inc
- RECRUITINGEarly Phase 1NCT04532268A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHLZhejiang University
- ACTIVE NOT RECRUITINGPhase 2NCT04245839A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)Celgene · PI: Bristol-Myers Squibb
- ACTIVE NOT RECRUITINGPhase 2NCT04234061Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell LymphomaPeter MacCallum Cancer Centre, Australia · PI: Michael Dickinson
- RECRUITINGPhase 2NCT05470777CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1, PHASE2NCT05950165A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's LymphomaCho Pharma Inc.
- ACTIVE NOT RECRUITINGPhase 2NCT04148430A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell TherapyMemorial Sloan Kettering Cancer Center · PI: Jae Park, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04077723A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaHoffmann-La Roche · PI: Clinical Trials
- ACTIVE NOT RECRUITINGPhase 1NCT03696784Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell LymphomaUNC Lineberger Comprehensive Cancer Center · PI: Natalie Grover, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03620578DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBLStichting Hemato-Oncologie voor Volwassenen Nederland · PI: M. ED Chamuleau, MD PhD
- RECRUITINGPHASE1, PHASE2NCT03356054Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First RelapseStichting Hemato-Oncologie voor Volwassenen Nederland · PI: P.J. Lugtenburg, Dr.
- RECRUITINGPHASE1, PHASE2NCT03223610Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaNational Cancer Institute (NCI) · PI: Christopher J Melani, M.D.
- RECRUITINGPhase 1NCT03017820A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaMayo Clinic · PI: Nora Bennani, M.D.
- ACTIVE NOT RECRUITINGPhase 1NCT02992522Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaBeth Christian · PI: Beth Christian, MD